LATEST NEWS
December 08, 2016 | Company Announcements
Bavarian Nordic Introduces New Incentive Programs for Executive Management and Employees November 23, 2016 | Company Announcements
Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox VaccineNovember 23, 2016 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise November 09, 2016 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2016 October 18, 2016 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine September 13, 2016 | Company Announcements
Bavarian Nordic Issues Financial Calendar for 2017August 31, 2016 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise August 17, 2016 | Company Announcements
Bavarian Nordic Announces First Half 2016 Results August 15, 2016 | Company Announcements
Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study July 27, 2016 | Company Announcements
Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine